JPH0532373B2 - - Google Patents
Info
- Publication number
- JPH0532373B2 JPH0532373B2 JP58042722A JP4272283A JPH0532373B2 JP H0532373 B2 JPH0532373 B2 JP H0532373B2 JP 58042722 A JP58042722 A JP 58042722A JP 4272283 A JP4272283 A JP 4272283A JP H0532373 B2 JPH0532373 B2 JP H0532373B2
- Authority
- JP
- Japan
- Prior art keywords
- disintegrant
- mesh
- particle size
- fine powder
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000007884 disintegrant Substances 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 18
- CHRHZFQUDFAQEQ-UHFFFAOYSA-L calcium;2-hydroxyacetate Chemical compound [Ca+2].OCC([O-])=O.OCC([O-])=O CHRHZFQUDFAQEQ-UHFFFAOYSA-L 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 description 14
- 239000001913 cellulose Substances 0.000 description 13
- 229920002678 cellulose Polymers 0.000 description 13
- 235000010980 cellulose Nutrition 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 239000007916 tablet composition Substances 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000006266 etherification reaction Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- BXKDSDJJOVIHMX-UHFFFAOYSA-N edrophonium chloride Chemical compound [Cl-].CC[N+](C)(C)C1=CC=CC(O)=C1 BXKDSDJJOVIHMX-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4272283A JPS59167522A (ja) | 1983-03-14 | 1983-03-14 | 固型薬剤の製造法 |
| KR1019840000850A KR840007590A (ko) | 1983-02-23 | 1984-02-22 | 아졸 치환 알콜 유도체의 제조방법 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4272283A JPS59167522A (ja) | 1983-03-14 | 1983-03-14 | 固型薬剤の製造法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59167522A JPS59167522A (ja) | 1984-09-21 |
| JPH0532373B2 true JPH0532373B2 (de) | 1993-05-14 |
Family
ID=12643955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4272283A Granted JPS59167522A (ja) | 1983-02-23 | 1983-03-14 | 固型薬剤の製造法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59167522A (de) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5247914A (en) * | 1975-10-11 | 1977-04-16 | Lilly Industries Ltd | Tablet and its prepation |
| JPS59155310A (ja) * | 1983-02-21 | 1984-09-04 | Daicel Chem Ind Ltd | 崩壊性の改良された固型薬剤の製造方法 |
-
1983
- 1983-03-14 JP JP4272283A patent/JPS59167522A/ja active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5247914A (en) * | 1975-10-11 | 1977-04-16 | Lilly Industries Ltd | Tablet and its prepation |
| JPS59155310A (ja) * | 1983-02-21 | 1984-09-04 | Daicel Chem Ind Ltd | 崩壊性の改良された固型薬剤の製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59167522A (ja) | 1984-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5616343A (en) | Cross-linked amylose as a binder/disintegrant in tablets | |
| US4983398A (en) | Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates | |
| EP0157695B1 (de) | Feste Arzneimittel-Darreichungsformen mit gesteuerter Freisetzung auf Basis von Mischungen aus wasserlöslichen nichtionischen Celluloseethern und anionischen Tensiden | |
| CA1287582C (en) | Sustained release compositions comprising hydroxypropyl cellulose ethers | |
| CA2686035C (en) | Robust rapid disintegration tablet formulation | |
| AU2007234864B2 (en) | Fast release paracetamol tablets | |
| JPH0751516B2 (ja) | 固体医薬製剤 | |
| KR20070116291A (ko) | 신속히 붕해되는 메틸셀룰로오스 정제 | |
| JP3534130B2 (ja) | 医薬品組成物 | |
| US5087454A (en) | Ibuprofen tablet | |
| JP2009513530A5 (de) | ||
| JP2686215B2 (ja) | 徐放性錠剤 | |
| IE903330A1 (en) | An analgesic composition and a method for its formulation | |
| JPH0532373B2 (de) | ||
| AU690417B2 (en) | Nsaid delivery employing a powdered hydrocolloid gum obtainable from higher plants | |
| JPH0526762B2 (de) | ||
| US5993860A (en) | NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants | |
| JPH0524139B2 (de) | ||
| AU632376B2 (en) | Pressing not delayed release of active compound, process for its production and use of polyhydroxybutyric acid for the production of such a pressing | |
| Khan | THE ROLE OF DISINTEGRANTS IN SOLID ORAL DOSAGE MANUFACTURING | |
| AU609234B2 (en) | Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates | |
| WO2009151090A1 (ja) | 炭酸カルシウム含有速崩壊性製剤 | |
| JP6651638B2 (ja) | 口腔内崩壊錠添加用組成物 | |
| JPH0526770B2 (de) | ||
| JP3815705B2 (ja) | 固形薬剤及びその製造方法 |